Newsroom
All News
- All News
- Events
- In the News
- Press Releases
- Publications
Data Presentation at Association for Molecular Pathology 2023 Validates Performance of SeptiCyte® RAPID in Immunocompromised Patients and Patients on Immunosuppressive Therapy
SeptiCyte® RAPID may aid clinicians in determining early antibiotic administration and in bundle compliance for immunocompromised patients with intermediate-high and high probabilities of sepsis SEATTLE and BRISBANE, Australia, Nov. 17, 2023 /PRNewswire/ -- Immunexpress, Pty Ltd., a molecular diagnostics company focused on rapid diagnosis and improved outcomes for suspected sepsis patients, today announced a poster presentation...
“Improving Outcomes For Patients With Sepsis” — Interview from Progress, Potential & Possibilities
https://www.youtube.com/watch?v=hv-Oy98PA6w "Today we have the honor of being joined by Dr Roland Carlson, who is the Chief Executive Officer of Immuneexpress which is a Seattle-based molecular diagnostic company they're committed to improving the outcomes for patients suspected of having sepsis and their FDA-cleared SeptiCyte technology is focused on rapidly quantifying...
Chart: Potential impact of a host response gene expression sepsis assay (septicyte rapid) in a tertiary emergency department setting
This chart will be presented by Immunexpress collaborators from Cone Health, Greensboro, NC. at the CHEST Annual Meeting in Honolulu, October on October 10th, 2023. CHEST SeptiCyte Chart for the 2023 CHEST annual meeting (downloadable, screen-readable pdf)
CHEST 2023 Poster Demonstrates the Utility of SeptiCyte® RAPID in Antibiotic Administration and Sepsis Bundle Compliance
This official press release was first published on PRNewswire SeptiCyte® RAPID may aid clinicians in making a determination on early antibiotic administration and in bundle compliance for patients with intermediate-high and high probabilities of sepsis SEATTLE and BRISBANE, Australia, Oct. 2, 2023 /PRNewswire/ -- Immunexpress, Pty Ltd., a molecular diagnostics company focused on rapid diagnosis...
Rollie Carlson joins the Med-Tech podcast to discuss early diagnosis of sepsis
Med-Tech's Ian Bolland interviewed Rollie Carlson, CEO of Immunexpress, about the challenges of diagnosing sepsis and the technology that is being developed to tackle it. https://soundcloud.com/medtalkpodcast/developing-technology-for-faster-sepsis-diagnosis
SeptiCyte® RAPID Receives ICD-10-PCS Code from the U.S. Centers for Medicare & Medicaid Services (CMS)
This post originally appeared on Cision PR Newswire ICD-10-PCS code to provide accurate documentation of sepsis diagnosis for medical claims using SeptiCyte® RAPID SEATTLE and BRISBANE, Australia, Sept. 6, 2023 /PRNewswire/ -- Immunexpress, Pty Ltd., a molecular diagnostics company focused on improving outcomes for suspected sepsis patients, today announced that the U.S. Centers for Medicare...
PodcastDX: Richard Brandon on Sepsis Rapid Test
Listen to the podcast: PodcastDX.com, episode S.14/E.19 Sepsis Rapid Test Show notes from the podcast Sepsis Rapid Test This week we will discuss a new rapid response test for Sepsis with one of the developers, Richard Brandon. Sepsis describes a syndrome that occurs when severe infection results in critical illness...
Immunexpress and University Hospitals Cleveland Medical Center Present Quality Improvement Feasibility with SeptiCyte® RAPID at the 2023 American Association for Clinical Chemistry Annual Scientific Meeting and Clinical Lab Expo
Immunexpress, Inc. 25 Jul, 2023, 16:30 ET SeptiCyte® RAPID, an in vitro diagnostic test intended to aid differentiating infection-positive (sepsis) from infection-negative systemic inflammation in patients suspected of sepsis, demonstrated good analytical performance SEATTLE and BRISBANE, Australia, July 25, 2023 /PRNewswire/ -- Immunexpress, Pty Ltd., a molecular diagnostic company focused...
In the News: Why Better Sepsis Diagnosis Results in Better Outcomes
In Clinical Lab Products, Silvia Cermelli, PhD, and Prashant Wani, PhD say "The delay in sepsis diagnosis not only increases the risk of dying by as much as 8% every hour, but misdiagnosis leads to unnecessary use of strong antibiotic therapies causing health-related burdens on patients and economic burdens on...
Immunexpress Announces Adoption of SeptiCyte® RAPID by FirstHealth of the Carolinas
SEATTLE and BRISBANE, Australia, July 20, 2023 /PRNewswire/ -- Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for patients suspected of sepsis, announced today the adoption of SeptiCyte® RAPID by FirstHealth of the Carolinas, a non-profit health system licensed for four hospitals in Pinehurst, Troy, Rockingham and Raeford, North Carolina. SeptiCyte RAPID will be available at FirstHealth...
Slice of Healthcare’s Big Breakthrough podcast features Richard Brandon, Chief Scientific Officer At Immunexpress
From the Slice of Healthcare podcast notes: What you’ll get out of this episode: Richard’s background Overview of Immunexpress The impact of a lack of reliable sepsis diagnostics SeptiCyte technology What’s next? https://youtu.be/jGLXeCJsMA4
In the news: A Diagnostic Dilemma
A sepsis thought leadership article from Richard Brandon PhD, CTO at Immunexpress has just been published in IDTransmission. Sepsis takes a heavy toll on society, causing millions of fatalities worldwide per year and costing upwards of US$50 billion yearly in the US alone. Sepsis can develop from viral, bacterial, and...
If you are a member of the media, please contact:
Scott Stachowiak
Russo Partners
(646) 942-5630
scott.stachowiak@russopartnersllc.com